Membrane-bound IL-7 immobilized by the CD8 transmembrane region improves efficacy of CD19 CAR-T cell therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Membrane-bound IL-7 immobilized by the CD8 transmembrane region improves efficacy of CD19 CAR-T cell therapy ; volume:23 ; number:1 ; day:23 ; month:10 ; year:2024 ; pages:1-6 ; date:12.2024
Molecular cancer ; 23, Heft 1 (23.10.2024), 1-6, 12.2024
- Creator
-
Zhang, Chaoting
Liu, Ting
Li, Shance
Teng, Xia
Zhu, Yuge
Zhang, Guanyu
Xie, Huimin
Sun, Kang
Tu, Jiaxin
Yang, Wenjun
Lu, Zheming
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-024-02154-0
- URN
-
urn:nbn:de:101:1-2501112116250.132925612235
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhang, Chaoting
- Liu, Ting
- Li, Shance
- Teng, Xia
- Zhu, Yuge
- Zhang, Guanyu
- Xie, Huimin
- Sun, Kang
- Tu, Jiaxin
- Yang, Wenjun
- Lu, Zheming
- SpringerLink (Online service)
Other Objects (12)
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia
Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Extracorporeal photopheresis as an option for controlling CRS and GvHD after CD19 CAR-T cell therapy
Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo
High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia
Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Extracorporeal photopheresis as an option for controlling CRS and GvHD after CD19 CAR-T cell therapy
Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo
High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia
Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Extracorporeal photopheresis as an option for controlling CRS and GvHD after CD19 CAR-T cell therapy
Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo